After kidney transplantation, it is necessary to check the renal function to determine whether Dagliflozin can be used or not, if the renal function is normal or mild renal insufficiency, it can be used, and if the renal insufficiency is moderate or severe, it can not be used. The details are as follows: 1. If renal function is normal or mild renal insufficiency, i.e., glomerular filtration rate (eGFR) >60ml/min1.73m^2 then you can take Dagliflozin normally. 2. Dagliflozin is not recommended if the glomerular filtration rate (eGFR) is 30-60ml/min1.73m^2. 3. Dagliflozin is contraindicated if the glomerular filtration rate (eGFR) <30ml/min1.73m^2. Dagliflozin belongs to the sglt2 inhibitors, which mainly reduces blood glucose by decreasing glucose reabsorption in the kidney and increasing urinary glucose and sodium excretion. Approximately 75% is excreted by the kidneys and approximately 21% is excreted in the feces. It can generally be used in patients without a history of severe hypersensitivity reactions or severe renal impairment. Common adverse reactions to this drug include hypotension, ketoacidosis, and genitourinary tract infections. Promptly consult an endocrinologist if there is any discomfort while taking the drug.